A study led by Meng revealed that SIL ameliorates myocardium fibrosis in rats with diabetic cardiomyopathy by inhibiting TGF-β1/Smad signaling, which is involved in TGFβR1 and TGFβR2 expression activation [92]. This evidence concerns the gene TGFBR1 and diabetic cardiomyopathy.